News for BridgeBio Pharma, Inc. (BBIO)

Deep Track Capital, LP, (together with its affiliates, ”œDeep Track” or ”œwe”), one of the largest shareholders of Dynavax Technologies Corporation (NASD

BridgeBio Pharma (BBIO) stock in focus as its 2024 spinout BridgeBio Oncology merges with Helix to form go public on Nasdaq under the ticker symbol BBOT. Read more here.

BridgeBio Pharma Inc (BBIO), a biopharmaceutical company focused on genetic diseases, announced on February 25, 2025, the pricing of $500 million in convertible

On February 24, 2025, BridgeBio Pharma Inc (BBIO) announced its intention to offer $500 million in convertible senior notes due 2031 in a private offering to qu

- Long term debt management strategy will strengthen the balance sheet without increasing total liabilities - Refinancing term debt facility lowers interest ex

BridgeBio Pharma (BBIO) announces $500M convertible notes offering to repay debt, reduce interest expenses, and boost flexibility.

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a look at where BridgeBio Pharma, Inc.

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -20.18% and 10.98%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

**media[545479]**

BridgeBio Pharma (BBIO) to report Q4 earnings on Feb 20. Analysts predict EPS of -$1.09 and revenue surge of 130.9% Y/Y to $4.04M.

High-rolling investors have positioned themselves bearish on BridgeBio Pharma BBIO, and it's important for retail traders to take note. \This activity came to o...

**media[540323]**

On December 31, 2024, Prosight Management, LP (Trades, Portfolio) executed a significant transaction involving Vincerx Pharma Inc (VINC), reducing its holdings

**media[537828]**

On Monday, the Dow Jones lost another 0.28 percent, while the S&P 500 and the Nasdaq Composite both registered steep declines of 0.76 percent and 1.20 percent, respectively.

On January 31, 2025, Andreas Halvorsen (Trades, Portfolio), a prominent figure in the investment world, made a significant move by reducing the holdings in Brid

As per the recent earnings update by FactSet dated 24th January 2025, the Q4 2024 earnings season for the S&P 500 has seen a strong start.

We recently compiled a list of the Billionaire Andreas Halvorsen's Top 15 Long-Term Stock Picks. In this article, we are going to take a look at where BridgeBio Pharma, Inc.

As of Jan. 21, 2025, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading d...